Skip to main content

Table 2 Change in health status and symptom scores of 4 the groups of COPD patients at exacerbations compared to stable visits

From: COPD exacerbation severity and frequency is associated with impaired macrophage efferocytosis of eosinophils

 

A (n = 10)

B (n = 16)

C (n = 19)

D (n = 58)

p value

Δ CRQ Fatigue (unit)

-1.36 (-2.61 to -0.12)*

-1.33 (-2.35 to -0.31)*

-1.11 (-1.76 to -0.45)*

-1.00 (-2.61 to -0.12)*

0.78

Δ CRQ Dyspnoea (unit)

-1.49 (-2.92 to -0.05)*

-1.05 (-2.32 to 0.21)*

-1.04 (-1.41 to -0.67)*

-0.57 (-0.98 to -0.15)*

0.34

Δ CRQ Emotion (unit)

-1.22 (-1.52 to -0.91)*

-1.07 (-2.00 to -0.14)*

-0.62 -1.27 to 0.02)*

-0.89 (-1.31 to -0.46)*

0.67

Δ CRQ Mastery (unit)

-0.99 (-2.33 to 0.36)*

-0.97 (-2.28 to 0.34)*

-1.10 (-1.99 to -0.21)*

-0.75 (-1.09 to -0.41)*

0.59

Δ CRQ total (unit)

-1.26 (-2.21 to -0.32)*

-1.12 (-1.99 to -0.22)*

-0.97 (-1.49 to -0.44)*

-0.79 (-1.04 to -0.55)*

0.54

Δ VAS cough (mm)

22 (3 to 42)*

35 (21 to 48)*

7 (3 to 42)*

27 (18 to 36)*

0.06

Δ VAS dyspnoea (mm)

34 (3 to 65)*

35 (20 to 51)*

17 (-2 to 35)

25 (17 to 33)*

0.31

Δ VAS sputum production (mm)

8 (-32 to 49)

24 (-2 to 50)

9 (-2 to 21)

21 (12 to 29)*

0.45

Δ VAS sputum purulence (mm)

28 (-13 to 68)

18 (-5 to 42)

31(17 to 45)*

15 (5 to 24)*

0.36

  1. Data presented as mean (95% CI) unless stated; *p < 0.05 stable versus exacerbation.